• HTA91 Indirect Comparisons in German AMNOG-Assessments: Keep the Faith

    Dec 1, 2024, 00:00

  • EPH17 Targeted Literature Review (TLR) on the Mortality in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) in the USA

    Dec 1, 2024, 00:00

  • HSD8 Treatment Patterns of Patients With Multiple Myeloma in South Korea Using a Common Data Model

    Dec 1, 2024, 00:00

  • HPR201 How Is the Unmet Medical Need Concept Applied in Marketing Authorization and PR Assessments? A Structured Document Analysis

    Dec 1, 2024, 00:00

  • HTA178 The Health Technology Assessment System in Portugal: A Study on Medicines Reimbursement Recommendations

    Dec 1, 2024, 00:00

  • EE642 Cost-Effectiveness of Febuxostat 120/80 Mg as a Second-Line After Allopurinol 100/300MG in Gout Patients in Algeria

    Dec 1, 2024, 00:00

  • HTA93 Mixture Cure Models: A New Paradigm to Model Long-Term Remission (LTR) for Chimeric Antigen Receptor (CAR) T-Cell Therapies?

    Dec 1, 2024, 00:00

  • HPR42 Socioeconomic Burden of Main Diseases in Eight Latin American Countries

    Dec 1, 2024, 00:00

  • EPH6 Understanding Mortality Risk Among COVID-19 Vaccinated Individuals in the US: A Literature Review

    Dec 1, 2024, 00:00

  • HSD60 Can the Use of Andon and a Dedicated Traffic Management Nurse Assist in Diagnosing Operational Issues in Surgical Centers?

    Dec 1, 2024, 00:00

  • HPR191 Utilization of a Managed Access Protocol to Enable Reimbursement of Liraglutide (Saxenda®) for Weight Management for Patients in Ireland

    Dec 1, 2024, 00:00

  • EPH236 Molecular Epidemiology of ROS1 Alterations in Advanced Non-Small Cell Lung Cancer (NSCLC): Temporal Patterns of Testing and Positivity Across Europe Between 2018 and 2022

    Dec 1, 2024, 00:00

  • HPR195 Implementing Health Technology Management of Medicines for Rare Diseases: A Case Study of Reimbursement of Medicines for Spinal Muscular Atrophy in Ireland

    Dec 1, 2024, 00:00

  • EE351 Societal Impact and Economic Burden of Lipodystrophy in Bulgaria

    Dec 1, 2024, 00:00

  • HTA186 Oxford Digital Biomarkers for Dementia (OxDBD): Lean Assessment Process Methodology for Evaluating Clinical Needs, Adoption Barriers, and As Precursor for Early Economic Evaluation and Adoption Strategy in Acute NHS Hospitals

    Dec 1, 2024, 00:00

  • HPR220 Coverage and Access Conditions of 4CMenB Vaccination Across Different Regions of Germany: A Retrospective Ecological Study

    Dec 1, 2024, 00:00

  • EPH275 Treatment Patterns and Patients’ Pathways in Actinic Keratosis Population: A Retrospective Longitudinal Cohort Study in the French National Health Insurance Claim Database (SNDS)—EPIKA Study

    Dec 1, 2024, 00:00

  • EPH244 Adverse Drug Reactions Due to Antitubercular Therapy in Multidrug-Resistant-Tuberculosis in North-East India

    Dec 1, 2024, 00:00

  • HTA199 Trends in Patient Organisation Submissions to the National Centre for Pharmacoeconomics

    Dec 1, 2024, 00:00

  • CO118 Indirect Treatment Comparison (ITC) of Avalglucosidase Alfa (AVA) vs Cipaglucosidase Alfa Plus Miglustat (Cipa+mig) in Late-Onset Pompe Disease (LOPD): An Updated Analysis Using Mixed-Model Repeated Measures (MMRM) Data

    Dec 1, 2024, 00:00

  • HSD16 Introduction of Faecal Calprotectin Testing Into the UK Inflammatory Bowel Disease Diagnostic Pathway Reduces Environmental Burden

    Dec 1, 2024, 00:00

  • HPR80 The Socioeconomic Burden of Migraine in Latin America: A Hidden Brake on Economic Growth?

    Dec 1, 2024, 00:00

  • EE785 Impact of Choices in Cost-Effectiveness Analysis of Recombinant Zoster Vaccine Among 65 Years Old and Older in France

    Dec 1, 2024, 00:00

  • HSD85 Racial and Ethnic Disparities in Receiving Mental Health Support Among Adolescents in the US

    Dec 1, 2024, 00:00

  • EE784 Cost-Effectiveness Analysis of Bimekizumab in Patients With Active Psoriatic Arthritis (PSA) in Greece

    Dec 1, 2024, 00:00

  • EE285 Conceptualization and Validation of a De Novo Cost-Effectiveness Analysis for Pulmonary Hypertension Associated With Interstitial Lung Disease

    Dec 1, 2024, 00:00

  • HTA205 Patients’ Journey and Healthcare Costs of Relapsing Early Breast Cancer in a Setting of Italian Real Clinical Practice

    Dec 1, 2024, 00:00

  • EE835 Improper Age-Adjustment of Health State Utilities in Cost-Effectiveness Models: Assessing the Impact and Key Drivers

    Dec 1, 2024, 00:00

  • HPR43 Future Proofing Policy for Adult Influenza Vaccines in the UK: The Case for Centralized Procurement

    Dec 1, 2024, 00:00

  • HSD131 Economic Evaluation of the Organizational Impact of Atezolizumab Subcutaneous in a French Hospital

    Dec 1, 2024, 00:00

  • P55 Navigating Change: A Comparative Analysis of Health Technology Assessment Reforms Across Agencies and Their Interdependencies

    Dec 1, 2024, 00:00

  • HPR130 The Role of Public Health Taxation of Unhealthy Goods on Generating Revenues for Health Insurance System: A Retrospective Analysis

    Dec 1, 2024, 00:00

  • HPR225 Impact of the 2021 US Federal X-Waiver Practice Guideline Change on the Prescribing of Buprenorphine and Naltrexone for Treating Opioid Use Disorder in Medicaid Population

    Dec 1, 2024, 00:00

  • EE681 Healthcare Resource Utilization for Children Under 15 Years Old With Type 1 Diabetics : A Retrospective, Multicenter Analysis

    Dec 1, 2024, 00:00

  • HTA99 Matching Insights From Clinical Experts and Generative AI for JCA PICO Validation

    Dec 1, 2024, 00:00

  • CO126 Core Outcome Sets in Cancer Clinical Trials: Current Status and Future Opportunities

    Dec 1, 2024, 00:00

  • EE434 The Cost-Effectiveness of Atidarsagene Autotemcel (arsa-cel) for the Treatment of Metachromatic Leukodystrophy (MLD) in Spain

    Dec 1, 2024, 00:00

  • EE509 Should Increase in Appropriate Self-Care Be Encouraged? Case Study on Economic Savings With Over-the-Counter (OTC) Ibuprofen in Dysmenorrhoea, Migraine, and Acute Rhinosinusitis in the UK

    Dec 1, 2024, 00:00

  • EE645 Costs and Healthcare Resource Utilization Associated With Chronic Spontaneous Urticaria: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • P40 The Effect of Biosimilar Entry on Biologic Drug Prices in Medicare Part B

    Dec 1, 2024, 00:00

  • EPH100 Pharmacological Oncological Treatment of Breast Cancer in the Slovak Republic in 2023: Results of the Nationwide Epidemiological Study Medi-LINE®.

    Dec 1, 2024, 00:00

  • HTA38 Is There Value in Utilizing Country-Specific Health Utility Values for Health Technology Assessment Submissions? Findings From a Case Study in Hematological Cancers

    Dec 1, 2024, 00:00

  • PT31 Reducing Health Inequality of Introducing SGLT2i Therapy in a Real-World Type 2 Diabetes Population With Diverse Patient Characteristics: A Distributional Cost-Effectiveness Analysis

    Dec 1, 2024, 00:00

  • EPH226 Polysubstance Use and Social Sequelae in Women of Reproductive Age With Recent Marijuana Use

    Dec 1, 2024, 00:00

  • EE292 Cost-Effectiveness Analysis of PCV20 3+1 Versus PCV15 2+1 Vaccination of the Pediatric Population in the Netherlands

    Dec 1, 2024, 00:00

  • HTA133 Patient Involvement Initiatives in HTAs: How Can We Do Better?

    Dec 1, 2024, 00:00

  • HPR87 Poland's Medical Fund Act: Progress of the New Fast-Track TLI Reimbursement Pathway

    Dec 1, 2024, 00:00

  • EE393 Economic Impact of COVID-19 Vaccination Programs on Healthcare Workers: A Comparative Model-Based Analysis in the US, UK, Japan, and the Netherlands

    Dec 1, 2024, 00:00

  • EE741 Budget Impact Analysis of Risdiplam in the Treatment of Newborn Spinal Muscular Atrophy Patients in Poland

    Dec 1, 2024, 00:00

  • P48 Primary Care Resource Utilization and Costs of Imminent Subsequent Fractures in Postmenopausal Women: A Distributed Network Analysis Using Data Mapped to OMOP Common Data Model From Five European Countries

    Dec 1, 2024, 00:00

  • CO1 Safety Investigation of Candesartan Induced Osteoarthritis: Real-World Data Analysis for Novel Signal Using Faers Database

    Dec 1, 2024, 00:00

  • HPR18 Unmet Medical Need in Patients With Paroxysmal Noctural Hemoglobinuria Treated With Complement 5 Inhibitors: Results From a Cross-Sectional Survey in Canada

    Dec 1, 2024, 00:00

  • HSD133 Biosimilar Drugs: Knowledge and Perceptions Among Pharmacists in Algeria

    Dec 1, 2024, 00:00

  • HPR103 Recent Developments in European Voluntary Cross-Border Collaborations in Joint HTA, Drug Pricing, Procurement, and Readiness for EU HTA Implementation

    Dec 1, 2024, 00:00

  • HSD98 Does Digital Health Improve Healthcare and Medicine Accessibility in Saudi Arabia?

    Dec 1, 2024, 00:00

  • HPR37 Inflation Reduction Act: Global Implications for Pricing and Reimbursement

    Dec 1, 2024, 00:00

  • EE710 Cost-Effectiveness of Foslevodopa/Foscarbidopa for the Treatment of Advanced Parkinson's Disease With Severe Motor Fluctuations and Hyperkinesia or Dyskinesia in Greece

    Dec 1, 2024, 00:00

  • HTA77 Replicating a Partitioned Survival Model From an ICER Report Using Generative AI

    Dec 1, 2024, 00:00

  • HPR158 Price Discrepancies Between Me-Too Drugs and the First-in Class of Antibiotics Family in Côte D'ivoire

    Dec 1, 2024, 00:00

  • EPH286 Insights on Early Prostate Cancer (PCa) Epidemiology and Treatment Pathways From an Online Modified Delphi Panel

    Dec 1, 2024, 00:00

  • HPR128 A Comparative Analysis of Requirements for Gaining Market Access of Digital Health Technologies in Germany, Spain, Poland, and Hungary

    Dec 1, 2024, 00:00

  • EE437 Cost-Effectiveness Analysis of a Non-Active Implant for Chronic Gastro-Oesophageal Reflux Disease in Spain

    Dec 1, 2024, 00:00

  • HTA41 The Use of the SF-36v2® Health Survey (SF-36), SF-12v2®, and SF-6D® in Health Technology Assessments

    Dec 1, 2024, 00:00

  • HPR199 Impact of the Innovative Licensing and Access Pathway (ILAP) Designation on Regulatory and Health Technology Assessment (HTA) Outcomes

    Dec 1, 2024, 00:00

  • EPH64 Recognition of Sepsis Presenting With Atypical Symptoms, in Hemodynamically Stable Patients

    Dec 1, 2024, 00:00

  • HTA73 Demonstrating the Value of Digital Solutions in Market Access

    Dec 1, 2024, 00:00

  • HPR22 Catastrophic Health Expenditures of Hypertensives Management and Care in Ghana: Estimating Incidence, Socioeconomic, and Sociodemographic Correlates

    Dec 1, 2024, 00:00

  • EE738 Economic Value of Dupilumab and Advanced Therapeutics in Patients With Type 2 Inflammatory Diseases in Italy: An Estimation of Healthcare Resource Utilization Cost Offsets

    Dec 1, 2024, 00:00

  • EE358 Systematic Literature Review on Economic Evaluations of Disease-Modifying Treatments in Multiple Sclerosis: Current Insights and Future Directions

    Dec 1, 2024, 00:00

  • EPH45 Increased Access to Subcutaneous Relative to Intravenous Drug Regimens by Women and Minority Racial/Ethnic Patients Using Belimumab or Tocilizumab Among US Medicare Beneficiaries

    Dec 1, 2024, 00:00

  • HPR189 To What Extent Are Oncology Submissions to the National Institute for Health and Care Excellence (NICE) Incorporating a Probabilistic Base Case?

    Dec 1, 2024, 00:00

  • EE546 Postpartum Depression: Systematic Literature Reviews of Economic Evaluations of Pharmacological and Non-Pharmacological Treatments, Utilities, Costs, and Healthcare Resource Use

    Dec 1, 2024, 00:00

  • P11 EQ-5D-Y in Children With Asthma or Eczema: Does Perspective Matter in Proxy-Reported Outcomes Assessment of Pediatric Populations?

    Dec 1, 2024, 00:00

  • HTA221 Market Access Challenges for Gene Therapies in Inherited Blood Disorders: A Retrospective Evaluation of HTA Outcomes for Sickle Cell Disease and Thalassemia

    Dec 1, 2024, 00:00

  • EE822 Willingness to Pay in Japan After the COVID-19 Pandemic

    Dec 1, 2024, 00:00

  • EE389 Cost Savings Analysis of Implementing Benchmark Best Practices for TAVI Patients in Europe

    Dec 1, 2024, 00:00

  • EPH101 Prevalence of Sickle Cell Disease in the Middle East: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • HPR75 Development of a Conceptual Framework for Analyzing the Role of the Public Sector in the Development of New Valuable Health Innovations

    Dec 1, 2024, 00:00

  • EPH88 Optimization Strategies to Achieve the Quintuple Aim in Health in Colombia: A Focus on Health Economics

    Dec 1, 2024, 00:00

  • EE550 Cost-Effectiveness Analysis of Brentuximab Vedotin in Combination With Doxorubicin, Vinblastine and Dacarbazine (AVD) in Newly Diagnosed Stage III Hodgkin Lymphoma in Italy

    Dec 1, 2024, 00:00

  • HSD82 Real World Patient Journey and Healthcare Resource Utilization of HR+/HER2- Breast Cancer Patients in the Brazilian Private Healthcare System

    Dec 1, 2024, 00:00

  • HSD114 A Pilot Project of Implementing P4P for Diabetes Management: Communication Strategy

    Dec 1, 2024, 00:00

  • HSD105 Treatment Strategies for Uveal Melanoma: A Systematic Review

    Dec 1, 2024, 00:00

  • HPR115 Oncology Branded Multi-Company Combinations (MCCs): Assessment of the Availability in France, Germany, Italy, Spain, England, Scotland, Canada, and Australia

    Dec 1, 2024, 00:00

  • Practicality, Validity, and Responsiveness of Using the Proxy Version of the Child Health Utility–9 Dimensions With Children Aged 2 to 5 Years

    Dec 1, 2024, 00:00

  • EE521 Comparing the Cost-Effectiveness of a Novel Minimally Invasive Surgical Therapy for Benign Prostatic Hyperplasia (BPH): A Swedish Perspective

    Dec 1, 2024, 00:00

  • EE457 Cost-Effectiveness of Dostarlimab Monotherapy for the Second-Line Treatment of Advanced or Recurrent dMMR/MSI-H Endometrial Cancer Patients Previously Treated With Platinum-Based Chemotherapy in Spain

    Dec 1, 2024, 00:00

  • EE435 The Economic Impact of Adopting a 4MM Pen Needle and Structured Education for Insulin Administration by Patients With Diabetes in Spain

    Dec 1, 2024, 00:00

  • HTA86 Indirect Comparisons and Network Meta-Analysis in Spanish Drug Positioning Reports for Price and Financing

    Dec 1, 2024, 00:00

  • HSD61 One-Year Healthcare Utilization in People With Multiple Sclerosis and Controls in Wales

    Dec 1, 2024, 00:00

  • HPR47 Does Orphan Drug Designation Lead to Reimbursement in EU5?

    Dec 1, 2024, 00:00

  • EPH258 Impact of SARS-CoV-2 on Child and Adolescent Mental, Behavioral, and Neurodevelopmental Disorders: A MarketScan by Merative Bayesian Structural Time-Series Analysis

    Dec 1, 2024, 00:00

  • HTA108 Artificial Intelligence Tools for PICO Prediction: A New Reality or a Future Dream?

    Dec 1, 2024, 00:00

  • EE657 The Costs of Schizophrenia: A Systematic Review

    Dec 1, 2024, 00:00

  • HPR94 Insurance Payments and Hospital Costs Among Patients With S T Segment Elevation Myocardial Infarction (STEMI) Undergoing Percutaneous Coronary Intervention (PCI) in US Hospitals

    Dec 1, 2024, 00:00

  • EE494 AI-Driven Virtual Assistance Interface for Excel-Based Economic Model

    Dec 1, 2024, 00:00

  • EE471 Identifying the Value Drivers in Obesity Treatment: A Targeted Review of Weight Loss Effects on Health Economic Outcomes

    Dec 1, 2024, 00:00

  • EE828 Developing Automated Decision Rules Based on Vaccine Cost to Identify Optimal Vaccination Strategies

    Dec 1, 2024, 00:00

  • EPH208 Prevalence of Pulmonary Nodules (PNs) in 2019 in the United States (US)

    Dec 1, 2024, 00:00

  • EPH81 Racial Variation in Prenatal Depression in a United States Population of Medicaid-Insured Pregnancies

    Dec 1, 2024, 00:00

  • EPH164 Clinical and Economic Burden of Obesity Among Hospitalized Patients in the United States

    Dec 1, 2024, 00:00

  • EPH104 Assessment of the Associations Between Obesity and Obesity-Related Comorbidities

    Dec 1, 2024, 00:00

  • EE543 Hospital Healthcare Resource Utilization in People With Cystic Fibrosis Treated With Elexacaftor/Tezacaftor/Ivacaftor in Portugal: A Non-Interventional, Retrospective Study

    Dec 1, 2024, 00:00

  • HPR19 Analysis of Oncology Drugs Reimbursement in Korea Over the Last Decade (2015-2024): Comparison of Clinical Value and Drug Price Levels

    Dec 1, 2024, 00:00

  • EE254 Cost-Effectiveness of Ginkgo Diterpene Lactone Meglumine Injection for Patients With Acute Ischemic Stroke in China

    Dec 1, 2024, 00:00

  • EE830 Exploring Long-Term Durability Assumptions in Cost-Effectiveness Models of Cell and Gene Therapies: A Study of 39 Health Technology Assessments

    Dec 1, 2024, 00:00

  • EE736 Economic Evaluation and Budget Impact Analysis of a Pay-for-Performance Pilot Program for Diabetes Treatment: A Global Decision-Making Guide

    Dec 1, 2024, 00:00

  • HTA131 Opportunities for Patient Involvement in HTA in the Philippines: Lessons From Guidelines in Europe, North America, and the Asia-Pacific

    Dec 1, 2024, 00:00

  • HTA163 An Assessment of the Application of the NICE Severity Modifier

    Dec 1, 2024, 00:00

  • EPH38 Epidemiology, Prognosis, and Healthcare Resource Use of Patients With Pulmonary Hypertension Associated With Lung Disease and/or Hypoxia in the UK

    Dec 1, 2024, 00:00

  • EE290 Cost Comparison Between the Use of Pertuzumab-Trastuzumab SC and IV Formulations to Treat HER2+ Breast Cancer Patients in Algeria

    Dec 1, 2024, 00:00

  • EE533 Cost-Effectiveness of Transcatheter Aortic Valve Implantation in Low Surgical Risk Symptomatic Severe Aortic Stenosis Patients in Brazil

    Dec 1, 2024, 00:00

  • EE297 Budget Impact Analysis of Cenobamate for Epilepsy Patients With Drug-Resistant Focal Onset Seizures in the Netherlands

    Dec 1, 2024, 00:00

  • EPH234 Estimation of Productivity-Adjusted Life Years (PALYs) and Condition-Specific PALY Loss Among the Late Middle-Aged Adults in China

    Dec 1, 2024, 00:00

  • HPR184 Recent Reforms in External Reference Pricing (ERP) in GCC Markets in the Context of Best Practice Guidelines for Use of ERP

    Dec 1, 2024, 00:00

  • CO106 Insights From Randomized Controlled Trials on the Efficacy and Safety of Pharmacological Therapies for Differentiated Thyroid Cancer: A Systematic Review

    Dec 1, 2024, 00:00

  • HSD3 Real-World Treatment Patterns in Sickle Cell Disease (SCD) in Europe, Africa, Eastern Mediterranean Region (EMR), and India: A Systematic Literature Review (SLR)

    Dec 1, 2024, 00:00

  • HPR65 Decision-Making in NICE, SMC, and NCPE: Assessing Time From Regulatory Approval to HTA Decision Outcome

    Dec 1, 2024, 00:00

  • EE646 Prescription Ratio and Costs of Intravitreal Injections for Diabetic Macular Oedema From 2015 to 2022

    Dec 1, 2024, 00:00

  • EE428 Healthcare Resource Utilization and Associated Costs in Patients With Eosinophilic Granulomatosis With Polyangiitis (EGPA) in England: A Retrospective Observational Cohort Study

    Dec 1, 2024, 00:00

  • EE683 Clinical Evolution and Medical Resource Utilization in Adults With Respiratory Syncytial Virus Infection at a Community Hospital in Argentina

    Dec 1, 2024, 00:00

  • HSD87 Evaluation of the Impact and Effectiveness of Support Services on the Use of Assistive Technologies

    Dec 1, 2024, 00:00

  • EPH225 Dermatologists’ Perspectives and Real-World Assessment of Alopecia Areata Severity Among Adults in Taiwan

    Dec 1, 2024, 00:00

  • CO128 The Association Between Intra- and Post-Operative Surgical Complications and Clinical and Economic Outcomes in Patients Undergoing Open Right Colectomy in the US

    Dec 1, 2024, 00:00

  • EPH87 Outcome Inequalities in Multiple Myeloma Patients in England: Incidence and Survival Rates Stratified by Ethnicity and Index of Multiple Deprivation

    Dec 1, 2024, 00:00

  • EE537 A Cost-Benefit Analysis of Proton Therapy in Cancer Treatment: Enhancing Jordan's Medical Tourism

    Dec 1, 2024, 00:00

  • HPR212 Contrast the Health System in Colombia: Social Insurance, Social Health, and Proposed Reform Models

    Dec 1, 2024, 00:00

  • HTA126 A Review of the Use of Indirect Treatment Comparisons to Support Health Technology Assessments in France

    Dec 1, 2024, 00:00

  • PT35 Are Social Impact Bonds the Answer to Limited Healthcare Resources for Improving Health Promotion and Disease Prevention?

    Dec 1, 2024, 00:00

  • EPH210 Landscape of Intrahepatic Cholangiocarcinoma (IHC) in Brazilian Public Healthcare System and Monitoring of the Technological Horizon

    Dec 1, 2024, 00:00

  • EPH20 How Do EQ-HWB Items Perform in Low Cognition Population?

    Dec 1, 2024, 00:00

  • EE705 Cost-Effectiveness Model of Lebrikizumab Compared to Dupilumab in the Treatment of Austrian Patients With Moderate to Severe Atopic Dermatitis

    Dec 1, 2024, 00:00

  • HTA35 Health Technology Appraisals of Gene Therapies Appraised Through NICE Highly Specialized Technology Route

    Dec 1, 2024, 00:00

  • EE600 Cost-Effectiveness and Budget Impact Analysis of Introducing Artificial Intelligence-Aided Colonoscopy for Adenoma Detection and Characterization in Spain

    Dec 1, 2024, 00:00

  • EE505 Cost-Effectiveness Analysis of Contemporary Advanced Prostate Cancer Management: A Markov Model for the Canadian Context

    Dec 1, 2024, 00:00

  • HSD130 Ιdentifying the Relationship Between Quality of Life and Fatigue of Patients With Chronic Renal Failure Undergoing Dialysis Treatment in Greece

    Dec 1, 2024, 00:00

  • HSD12 Routes to Diagnosis for Lung Cancer in England: Examining the Patient Journey Using Linked Data From Hospital Episode Statistics and the Diagnostic Imaging Database

    Dec 1, 2024, 00:00

  • EE711 Cost Effectiveness of Intravenous Versus Oral Cytomegalovirus Treatment in Recipients of Allogeneic Hematopoietic Cell Transplant From Tunisian Hospital Perspective

    Dec 1, 2024, 00:00

  • EE826 Real-World Oral Glucocorticoid Use in Systemic Lupus Erythematosus: A Nation-Wide Population-Based Study Using the French National Medico-Administrative Database

    Dec 1, 2024, 00:00

  • HTA92 NICE's Severity Modifier: Insights From Recent Appraisals

    Dec 1, 2024, 00:00

  • HTA154 Estimating Caregiver Spillovers Using Within-Trial Data for Use in Economic Evaluation: An Analysis of Caregiver EQ-5D and Patient Data Collected in the Episode Study on Seizure Dogs for Persons With Severe Refractory Epilepsy

    Dec 1, 2024, 00:00

  • HTA114 Characterizing Oncology Outcomes in Canada's Drug Agency (CDA-AMC) Reviews From 2022 -2023

    Dec 1, 2024, 00:00

  • HPR144 Netflix and Pills: Innovative Reimbursement Mechanisms for Antibiotics in Europe

    Dec 1, 2024, 00:00

  • EE298 Revealing the Unseen Burden: A Comprehensive Analysis of Social and Economic Burden of Atopic Dermatitis on Patients, Caregivers, and Their Perception on the Health System´s Response to Their Unmet Needs in Argentina

    Dec 1, 2024, 00:00

  • P54 An Insight Into Real-World Evidence (RWE) As a Component of Submission to NICE CADTH in the Last 3 Years

    Dec 1, 2024, 00:00

  • EE274 An Open Systematic Review on Methodology and Quality of Economic Evaluations of Breast Cancer Screening Strategies

    Dec 1, 2024, 00:00

  • EE427 Spotlight on mRNA Post-Vaccination Reactions: Should First-Generation, Influenza mRNA Candidates Have a Place in U.S. Adult Seasonal Immunization?

    Dec 1, 2024, 00:00

  • HTA208 Outcomes of Benefit Reassessments of Orphan Drugs in Germany After Exceedance of the Lowered Sales Threshold of 30 Million Euros

    Dec 1, 2024, 00:00

  • EE360 Economic Impact of Adopting Lanreotide for Patients With Acromegaly and GEP-NET in Qatar

    Dec 1, 2024, 00:00

  • CO9 Systematic Literature Review (SLR) of Disease Burden Related to First-Line (1L) Unresectable, Locally Advanced, or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

    Dec 1, 2024, 00:00

  • EE633 Obesity Impact in the Economic Burden of Invasive Pneumococcal Disease in Hospitalised Adults in Portugal: The Sphere Study

    Dec 1, 2024, 00:00

  • HPR99 Does HTA Undermine the Goals of EMA Authorization Pathways? Time to Availability of Drugs Licensed Under Conditional Marketing Authorization Compared to Standard Marketing Authorization

    Dec 1, 2024, 00:00

  • EPH241 Impact of COVID-19's Cancer Screenings in the United States of America, Canada, and Brazil: An International Comparative Study

    Dec 1, 2024, 00:00

  • CO112 The Most Often Utilized Clinical Endpoints for Assessing Treatment Efficacy in Nonalcoholic Fatty Liver or Nonalcoholic Steatohepatitis

    Dec 1, 2024, 00:00

  • EE776 Cost-Effectiveness of a 13-Valent Pneumococcal Conjugate Vaccine Compared With Currently Available Pneumococcal Conjugate Vaccines in Indian Children

    Dec 1, 2024, 00:00

  • HPR81 Pay-for-Performance Pilot Program for Diabetes Patients: Practical Example for Risk Group Stratification and Target Biomarker Values

    Dec 1, 2024, 00:00

  • EE291 Integrating a Markov Chain Monte Carlo Convergence Diagnostics Output Analysis (CODA) Into State Transition Cost-Effectiveness Models in Microsoft Excel: A Stepwise Approach

    Dec 1, 2024, 00:00

  • HSD64 Use of Not-Recommended Cancer Treatments Among Socio-Economically Disadvantaged Medicare Beneficiaries

    Dec 1, 2024, 00:00

  • EE467 A Cost-Effectiveness Analysis Comparing Two PFO Occluder Devices Using a Markov Model Simulation Over a 5-Year Time Horizon From a Match-Adjusted Indirect Treatment Comparison

    Dec 1, 2024, 00:00

  • EE791 Cost-Effectiveness Analysis of 1.5% Ruxolitinib Cream for the Treatment of Patients With Atopic Dermatitis in Canada

    Dec 1, 2024, 00:00

  • HPR55 Analysis of Leadtimes and Factors Impacting Leadtimes in Reimbursement Processes in the Netherlands to Estimate and Optimize Time Till Patient Access

    Dec 1, 2024, 00:00

  • HSD88 Current Epcoritamab Plus Rituximab and Lenalidomide (R2) Perceptions for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

    Dec 1, 2024, 00:00

  • EE305 Socio-Economic Burden of Alzheimer's Disease in Italy: A Multicenter Cost of Illness Study

    Dec 1, 2024, 00:00

  • HPR193 Evaluation of the Reimbursement Status and Market Access of Oncology Medicines in Türkiye: A Descriptive Analysis

    Dec 1, 2024, 00:00

  • EE787 Using Economic Evaluation for Investment Decisions in Health Infrastructure in Catalonia

    Dec 1, 2024, 00:00

  • EE250 Modeling the Potential Public Health Impact of Different COVID Vaccination Strategies With an Adapted Vaccine in Colombia

    Dec 1, 2024, 00:00

  • HSD19 Longitudinal Changes in Metabolic Syndrome Risk Factors (MSRF) Screening and Treatment Rates Between 2010 and 2021 Among Patients With Prostate Cancer (PCa) Treated With Androgen Deprivation Therapy (ADT)

    Dec 1, 2024, 00:00

  • HSD41 Hospital AI/ML Adoption by Neighborhood Social Vulnerability

    Dec 1, 2024, 00:00

  • EPH78 Prevalence of Depressive Symptoms Among College Students in Barranquilla, Colombia: A Cross-Sectional Study

    Dec 1, 2024, 00:00

  • P56 The Value of NICE Scientific Advice

    Dec 1, 2024, 00:00

  • CO11 Delayed Graft Function: More Than Just a Kidney Transplant Complication?

    Dec 1, 2024, 00:00

  • EE239 Who's Next? The Impact of Ranked Substitution on Budget Impact Model Uncertainty

    Dec 1, 2024, 00:00

  • HTA113 Comparative Analysis of Traditional vs AI-Assisted Health Technology Assessment Dossier Writing

    Dec 1, 2024, 00:00

  • EE727 Determining Survival Impact and Cost-Effectiveness of Multi-Gene Panel Sequencing in Metastatic Colorectal Cancer With Super Learning Approaches

    Dec 1, 2024, 00:00

  • HPR63 Evaluating National Healthcare Service Spending With Progression Free Survival-Based Models Versus Traditional Reimbursement Schemes for Breast and Lung Cancer in Italy

    Dec 1, 2024, 00:00

  • HTA172 Type of Clinical Evidence and Its Impact on Price Reductions for Oncology Drugs: A Review of Reimbursement Submissions in Canada

    Dec 1, 2024, 00:00

  • EPH9 Influence of Front Nutritional Labeling on Consumer Choices Related to Ultra-Processed Foods: Scoping Review

    Dec 1, 2024, 00:00

  • HTA15 Oncology Patient and Caregivers’ Perspectives on Value Assessment Frameworks: A Qualitative Study

    Dec 1, 2024, 00:00

  • HTA7 Hurdles to Reimbursement for GLP-1 Therapies in Weight Management

    Dec 1, 2024, 00:00

  • EPH103 Incidence of Solar Retinopathy and Photokeratitis in Private Clinic Post 2017 and 2024 Solar Eclipses Across the USA

    Dec 1, 2024, 00:00

  • EPH3 Effectiveness of Additional Risk Minimization Measures When Using Baricitinib (RISK-BARI): Preliminary Analysis

    Dec 1, 2024, 00:00

  • EE420 How Could ATMPs Demonstrate an Economic Benefit for Payers and What Are the Real-World Examples of This?

    Dec 1, 2024, 00:00

  • EE575 Cost-Effectiveness Analysis of Liso-Cel in the Treatment of Patients With Refractory or Relapsed Large B-Cell Lymphoma Within 12 Months (LBCL RR≤12) Eligible for Autologous Hematopoietic Stem Cell Transplant (ASCT) in France

    Dec 1, 2024, 00:00

  • EPH27 Medical Costs of Adults With COVID-19 in Dominican Republic (DR) During the Endemic Phase: A Micro-Costing Study

    Dec 1, 2024, 00:00

  • HPR93 Analysis of Real-World Evidence Role in US FDA Approvals of Novel Drugs and Post Marketing Requirements of RWE Study (Novel Drug Approvals US FDA 2023)

    Dec 1, 2024, 00:00

  • HPR227 Price Regulation of Combination Drug Therapies in Germany: Can Real-World Data Drive Flat-Rate Discounts?

    Dec 1, 2024, 00:00

  • EE570 Economic Evaluation of Tislelizumab for the Treatment of Second-Line Oesophageal Squamous Cell Carcinoma: A Lifetime Partition Survival Model

    Dec 1, 2024, 00:00

  • EE302 Impact of sFlt-1/PlGF Ratio Testing for Early Preeclampsia Detection on Healthcare Resource Utilization in Routine Pregnancy Management

    Dec 1, 2024, 00:00

  • EE415 Parameterization of Economic Burden Attributable to Atherosclerosis Cardiovascular Disease and Its Subtypes: A Nationwide, Population-Based Cohort Study

    Dec 1, 2024, 00:00

  • EE346 Comparative Cost and Saving Analysis of Insulin Glargine-300U/mL (Gla-300) vs Insulin Degludec 100 U/mL in the Treatment of Type 2 Diabetes Mellitus Based on the BRIGHT Study

    Dec 1, 2024, 00:00

  • HTA169 Do NICE’s Severity Modifier Criteria Identify Severe Conditions: An Update

    Dec 1, 2024, 00:00

  • HTA175 Navigating RWE Strategies in HTA Submissions for Ultra-Rare Diseases in Key European Healthcare Systems

    Dec 1, 2024, 00:00

  • HTA23 Application-Related Data Collection During Early Benefit Assessments in Germany: An Analysis of Current Procedures

    Dec 1, 2024, 00:00

  • EE413 Humanistic, Economic, and Social Impact of Lysosomal Storage Disorders in Spain

    Dec 1, 2024, 00:00

  • EE775 Treatment Cost for CDK 4/6 Inhibitors for HR+/HER2- Advanced and Metastatic Breast Cancer Patients in Portugal Based on Real-World Dosing Patterns: Insights From the PORTRAIT Study

    Dec 1, 2024, 00:00

  • HPR66 Readiness Assessment for Cervical Cancer Elimination in Europe

    Dec 1, 2024, 00:00

  • HSD69 Strategies to Enhance Virtual Medical Consultations Adoption in Saudi Arabia's Healthcare System

    Dec 1, 2024, 00:00

  • EE318 Review of the Economic Evaluations of Advanced Therapy Medicinal Products (ATMPs) Assessed by the French National Authority for Health (HAS)

    Dec 1, 2024, 00:00

  • CO45 Comparison of Targeted Therapy in Adult Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)

    Dec 1, 2024, 00:00

  • HTA156 Assessing the Generalizability of Automating Adaptation of Excel-Based Cost-Effectiveness Models Using Generative AI

    Dec 1, 2024, 00:00

  • HTA110 Acceptance of Cure Assumptions in NICE Oncology Technology Appraisals: Remission Impossible?

    Dec 1, 2024, 00:00

  • EPH68 Introduction of a New Dengue Vaccine (TAK-003) in Brazil's Public Health System: Impact on Public Health and Cost-Effectiveness Across Different Age Groups

    Dec 1, 2024, 00:00

  • HTA193 Comparison of Systematic Literature Review Requirements Among Health Technology Assessment Agencies in the UK and Ireland

    Dec 1, 2024, 00:00

  • HTA159 Approaches to Consider Spillover Effects Among Significant Others in Decisions About Health Care Interventions

    Dec 1, 2024, 00:00

  • EE753 Using State Sequence Analysis Alongside a Cost of Illness Study: Application to the Pathway of Heart Transplant Candidates in a French Heart Transplant Center

    Dec 1, 2024, 00:00

  • CO111 Indirect Treatment Comparisons of Lefamulin Versus Omadacycline for the Treatment of Community-Acquired Pneumonia

    Dec 1, 2024, 00:00

  • HTA27 A Targeted Literature Review of Treatment Effect Waning Methods for Early-Stage Immunotherapies in NICE Technology Appraisals

    Dec 1, 2024, 00:00

  • EPH49 Labour Productivity Impact of Respiratory Infections in the Netherlands

    Dec 1, 2024, 00:00

  • P52 Incorporating Equity Into UK Decision-Making: The Need for Better Equity Data for Distributional Cost-Effectiveness Analysis

    Dec 1, 2024, 00:00

  • HTA228 Missed Opportunities in Cost-Effectiveness Analyses for Rare Disease Treatments: A Systematic Review of Uncaptured Benefits Reported in NICE Highly Specialized Technology Assessments

    Dec 1, 2024, 00:00

  • EPH153 A Systematic Review of Risk Factors in Adolescents’ Predictors of High Blood Pressure in Adulthood

    Dec 1, 2024, 00:00

  • EPH199 Health Impact and Burden of Illness in Immune Thrombocytopenia: A Literature Review on Clinical, Humanistic, and Economic Burden

    Dec 1, 2024, 00:00

  • EPH114 Facilitating Real-World Data Discoverability and Transparency of Real-World Evidence to Support Research and Regulatory Decision-Making: The HMA-EMA Real-World Data Catalogues of Data Sources and Studies

    Dec 1, 2024, 00:00

  • HPR108 Exploring Health Crisis in Developing Nations: A Study of COVID-19's Impacts on Healthcare Access and Resilience

    Dec 1, 2024, 00:00

  • EE618 The Societal Cost of Duchenne Muscular Dystrophy in Brazil: A Burden of Illness Study

    Dec 1, 2024, 00:00

  • HPR60 Patients' Health Care Resources Utilization and Costs Estimation Across Cardiovascular Risk Categories: Insights From the Latino Study

    Dec 1, 2024, 00:00

  • HSD83 Multimorbidity Healthcare Delivery Models: An Approach to the Current Situation in Colombia

    Dec 1, 2024, 00:00

  • EE762 Cost of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Serbia

    Dec 1, 2024, 00:00

  • HTA94 Impact of Real-World Evidence in the HTA Process in Fran Analysis of Transparency Commission Appraisals in Rare Diseases

    Dec 1, 2024, 00:00

  • EPH231 Demographic and Clinical Characteristics of Implantable Cardioverter Defibrillator (ICD) Recipients: A 30 Year Analysis From the Island of Crete

    Dec 1, 2024, 00:00

  • HTA56 Implementation of Early Scientific Advice and Public Engagement for the HTA Development in Ukraine

    Dec 1, 2024, 00:00

  • EE531 Evaluation of the Cost-Effectiveness of a Nationwide Precision Medicine Program for Patients With Advanced Non-Small Cell Lung Cancer in Germany

    Dec 1, 2024, 00:00

  • CO57 Clinical and Patient-Reported Outcomes Associated With Oral Semaglutide Use in Adults With Type 2 Diabetes: A Pooled Analysis of Six Pioneer Real Prospective Real-World Studies

    Dec 1, 2024, 00:00

  • EE571 Economic Analysis of Liquid-Based Cytology for Cervical Cancer Prevention in Women in Austria

    Dec 1, 2024, 00:00

  • CO72 Bimekizumab: Matching-Adjusted Indirect Comparison (MAIC) to Establish 1-Year Comparative Efficacy in Moderate-to-Severe Hidradenitis Suppurativa (HS)

    Dec 1, 2024, 00:00

  • EE370 Evaluating the Impact of Implementing Nitrous Oxide Destruction Technology in NHS Labor Wards

    Dec 1, 2024, 00:00

  • EPH131 Disease Occurrence Clearly Impacts Eating Behavior: A Cross-Sectional Study Among Jordanians

    Dec 1, 2024, 00:00

  • CO48 Population Impact of Performing HRR Testing for Metastatic Castration-Resistant Prostate Cancer Treatment in the US

    Dec 1, 2024, 00:00

  • EE780 Internal Validation of the Metabo-Reno-Cardiovascular Disease Model: Mortality in Type 1 Diabetes

    Dec 1, 2024, 00:00

  • EPH196 Prognostic Factors in Thymic Cancer: Insights From a Systematic Literature Review

    Dec 1, 2024, 00:00

  • EE777 Diagnostic Pathways for Prostate Cancer in Italy: A Cost-Consequences Analysis

    Dec 1, 2024, 00:00

  • EE621 Treatment Cost of Heavily Treatment-Experienced Adult Patients With Multi-Drug Resistant HIV-1 Infection in Brazil

    Dec 1, 2024, 00:00

  • HTA63 Cost-Effectiveness of Empagliflozin in the Treatment of Patients With Chronic Kidney Disease in France

    Dec 1, 2024, 00:00

  • EPH188 Development and Graphical Illustration of a Data-Based Analysis Combining the Regional Distribution of Patient Cohorts With Availability, Distribution, and Caseload of In- and Outpatient Specialists

    Dec 1, 2024, 00:00

  • EPH58 Potential Public Health Impact of Respiratory Syncytial Virus (RSV) Vaccines for Prevention of Lower Respiratory Tract Disease (LRTD) Due to RSV Among Older Adults in Canada

    Dec 1, 2024, 00:00

  • EE612 Characterize the Economic Burden of Invasive Meningococcal Infection in France Using an Innovative Clustering Method

    Dec 1, 2024, 00:00

  • HPR23 Comparative Analysis of Medicines Reimbursement in Fran Rare Diseases Versus Other Conditions

    Dec 1, 2024, 00:00

  • HPR246 Oncology Drug Prices in the United States and Spain: Implications for Pricing Strategy and Drug Access

    Dec 1, 2024, 00:00

  • EPH67 Empty Bottles, Rising Risks: A Case-Crossover Study on Psychotherapeutic Medication Depletion and Suicide Triggers

    Dec 1, 2024, 00:00

  • EE730 Health Care Resource Utilization (HCRU) in Chronic Obstructive Pulmonary Disease (COPD), and Asthma Patients With Moderate-to-Severe Disease

    Dec 1, 2024, 00:00

  • EE806 Assessing the Public Health Benefit and the Broader Economic Value of Cardiovascular Risk Reduction With Icosapent Ethyl in Greece

    Dec 1, 2024, 00:00

  • EE326 Cost-Effectiveness of Spleen Aminopeptide Oral Solution in the Treatment of Adenoid Hypertrophy in Children

    Dec 1, 2024, 00:00

  • EE463 Cost of Chronic Myeloid Leukaemia Treatment in Türkiye: Results of a Delphi Panel Approach

    Dec 1, 2024, 00:00

  • EE716 Unlocking Pricing Power With Threshold Analysis: Conclusions From a Hypothetical Markov Model

    Dec 1, 2024, 00:00

  • EE676 Economic Burden and Unmet Needs of Retinitis Pigmento Expert Perspective in Brazil and Mexico

    Dec 1, 2024, 00:00

  • EE760 Is There a Place for First-Generation mRNA Seasonal Influenza Vaccines? Unraveling the Clinical and Economic Consequences of Increased Reactogenicity in U.S. Older Adults

    Dec 1, 2024, 00:00

  • HTA209 How Do Post-Registration Studies Impact Drug Evaluation by the Transparency Committee?

    Dec 1, 2024, 00:00

  • HTA187 Barriers Delaying the Implementation of Artificial Intelligence-Based Literature Reviews (AILRs) by Health Technology Assessment (HTA) Bodies

    Dec 1, 2024, 00:00

  • HPR91 Price Sensitivity and Uptake of Pharmaceuticals in Sweden and Finland: The Example of New Migraine Drugs

    Dec 1, 2024, 00:00

  • EE541 Cost-Effectiveness Analyses of Acute Ischemic Stroke Care Pathways: A Model for Different Scenarios and Countries

    Dec 1, 2024, 00:00

  • CO34 CAR T-Cell Therapy and the Emerging Threat of Secondary Cancers: A Targeted Look

    Dec 1, 2024, 00:00

  • HPR231 Equity Analysis in Accessibility of Chinese National Reimbursement Drug List

    Dec 1, 2024, 00:00

  • EE665 Health Care Resource Use and Costs of Hemophilia A (HA) in French Adult Patients in 2022: A Nationwide Claims Database Analysis

    Dec 1, 2024, 00:00

  • EE677 Consolidating Methods of Cost-Utility Analysis for Newborn Screening of Spinal Muscular Atrophy: A Systematic Review

    Dec 1, 2024, 00:00

  • CO80 Comparison of Conventional Chemotherapy Regimens in Adults With Acute Lymphoblastic Leukemia: A Systematic Review and Pooled Survival Analysis

    Dec 1, 2024, 00:00

  • HPR5 Visualizing Reimbursement Criteria for Digital Health Tools in Belgium and France

    Dec 1, 2024, 00:00

  • HPR216 International Reference Pricing Analysis of Medicines in Türkiye by 2023

    Dec 1, 2024, 00:00

  • PT21 Promoting Access to Innovative Drugs: A Review of National Drug Price Negotiation in China

    Dec 1, 2024, 00:00

  • HTA6 Predicting Picos to Prepare for Joint Clinical Assessment: Learnings From 19 Case Studies

    Dec 1, 2024, 00:00

  • CO86 A Systematic Literature Review (SLR) of Real-World Evidence (RWE) on the First-Line Treatment of Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer (NSCLC) With Immunotherapy

    Dec 1, 2024, 00:00

  • HSD110 Statin Prescribing in Patients With Non-Alcoholic Steatohepatitis in the United States: An Analysis of 3 Real-World Data Sources

    Dec 1, 2024, 00:00

  • EE812 Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for Mild-to-Moderate and Moderate-to-Severe Alzheimer's Disease Patients in USA

    Dec 1, 2024, 00:00

  • HSD31 Patient and TreatmentCharacteristics of New Users of SGLT-2i and/or ARNi in HFrEF Patients With and Without T2DM: A Real-World Data Analysis Based on German Claims Data

    Dec 1, 2024, 00:00

  • EPH270 Kota: The Emerging Suicide City of India

    Dec 1, 2024, 00:00

  • EE268 Interim Burden of Disease Findings for Myasthenic Gravis-Resource Utilization Epidemiology, Survival, and Treatment Patterns (MG-REST) Study in Ontario, Canada

    Dec 1, 2024, 00:00

  • EE338 Cost-Effectiveness of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis Versus Current Use of Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine or No PrEP to Prevent HIV-1 in Individuals at High Risk in Spain

    Dec 1, 2024, 00:00

  • EE469 Cost-Utility Analysis of Nutrient-Dense Supplementation in Undernourished Children in Indonesia

    Dec 1, 2024, 00:00

  • EE772 A Systematic Review and Distributional Cost-Effectiveness Analysis of Hearing Health Care in Chile: Equity Concerns and Trade Offs for Bone Conduction Implants

    Dec 1, 2024, 00:00

  • CO121 Population-Average Effect Estimates of Quizartinib and Midostaurin in Newly Diagnosed Patients With FLT3-Internal-Tandem-Duplication-Positive Acute Myeloid Leukaemia, Using Multi-Level Network Meta-Regression

    Dec 1, 2024, 00:00

  • HPR134 Impact of Loss of Exclusivity on the Expenditure of Medicines: An Analysis on Molecules for Which a Generic or Biosimilar Was Introduced in the Netherlands After 2012

    Dec 1, 2024, 00:00

  • EE366 The Cost-Effectiveness of Maribavir for Post-Transplant Refractory Cytomegalovirus Infection in France

    Dec 1, 2024, 00:00

  • EPH85 Association Between Schizophrenia and Subsequent Cancer Diagnoses: A Retrospective Cohort Study From Germany

    Dec 1, 2024, 00:00

  • EE349 Budget Impact Analysis of Birch Triterpenes for Patients With Epidermolysis Bullosa From a United States Perspective

    Dec 1, 2024, 00:00

  • HTA25 Diverging Relative Clinical Benefit Assessment Across HAS and G-BA: A Forecast for EU HTA in Oncology Drugs

    Dec 1, 2024, 00:00

  • EPH223 Trends in Epidemiology and Mortality of Patients With Melanoma in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • CO19 Comparative Analysis of Health Outcomes in Gestational Diabetes Mellitus: Diet-Controlled Vs. Insulin/Hypoglycemic-Controlled Methods

    Dec 1, 2024, 00:00

  • EE248 Burden of Disease From Acute Respiratory Infections Due to Respiratory Syncytial Virus in Colombia: A Low- and Middle-Income Country With Universal Health Coverage

    Dec 1, 2024, 00:00

  • HSD108 Impact of Predictive Modelling and Application of Preventative Measures in Reducing Fall Rates in Domiciliary Care

    Dec 1, 2024, 00:00

  • CO60 Superior Cardiovascular Benefits of SGLT2 Inhibitors Over DPP4 Inhibitors for Severe Diabetic Kidney Disease: A Population-Based Cohort Study

    Dec 1, 2024, 00:00

  • HTA103 Assessing the Suitability of Real-World Data for Indirect Treatment Comparison Using NICE's Data Suitability Assessment Tool (DataSAT)

    Dec 1, 2024, 00:00

  • EE395 Health Care Resource Utilization and Cost of Chronic Lymphocytic Leukemia in Finland

    Dec 1, 2024, 00:00

  • EPH264 Associations Between Antihypertensive Drugs and Risk of Sight-Threatening Diabetic Retinopathy in People With Type 2 Diabetes: A Population-Based Cohort Study

    Dec 1, 2024, 00:00

  • HPR56 Exploring If a Price Premium Is Requested for Cancer Drugs That Seek Reimbursement on State-Subsidised Schemes in Ireland: An Analysis of Drugs That Have Undergone a Full HTA by the NCPE in Ireland Between 2019 and 2023

    Dec 1, 2024, 00:00

  • HTA220 AI-Assisted Review of NICE Guidance for Highly Specialized Technologies: Economic Modelling of Ultra-Rare Conditions

    Dec 1, 2024, 00:00

  • EE380 A Case Study of Real-World Health Resource Utilization and Costs in a Patient With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2), an Ultra-Rare Pediatric Disease

    Dec 1, 2024, 00:00

  • EE480 Healthcare Resource Utilization and Costs Related to Pertussis in Adults With and Without Underlying Conditions: A German Claims Data Analysis

    Dec 1, 2024, 00:00

  • Enhancing Patient Response to Patient-Reported Outcome Measures: Insights From a Leading Dutch University Hospital

    Dec 1, 2024, 00:00

  • EPH195 Optimizing Traumatic Brain Injury Care Pathways Using SNDS: Modeling Economic Impact and Socioeconomic Determinants of Pathways

    Dec 1, 2024, 00:00

  • EE490 Adverse Event (AE) Management Costs Associated With Immune Checkpoint Inhibitors (ICI) Approved for Various Advanced or Metastatic Cancers in the US

    Dec 1, 2024, 00:00

  • EPH115 Estimating the Public Health Impact of Pediatric Vaccination Programs on Invasive Pneumococcal Disease in France

    Dec 1, 2024, 00:00

  • EPH79 Impact of the COVID-19 Pandemic on Diabetes Mellitus Care in Portugal

    Dec 1, 2024, 00:00

  • Direct and Indirect Mapping of Assessment of Quality of Life - 6 Dimensions (AQoL-6D) Onto EQ-5D-5L Utilities Using Data From a Multicenter, Cross-Sectional Study of Malaysians With Chronic Heart Failure

    Dec 1, 2024, 00:00

  • EPH145 Association Between Metformin Use and Major Adverse Cardiac Events in Multiple Myeloma Patients With Type 2 Diabetes Mellitus Receiving Carfilzomib: A Population-Based Cohort Study

    Dec 1, 2024, 00:00

  • EPH151 The Burden of Hospital-Acquired Venous Thromboembolism to Patients and Healthcare Systems in Ten Countries: A Health-Economic Analysis

    Dec 1, 2024, 00:00

  • HTA223 How to Speed Up the Process of Introducing High-Value Innovative Technologies to the Health System: The Catalan Health System Innovation Access Program (PASS)

    Dec 1, 2024, 00:00

  • P44 Examining the Prediction Properties of a Visual Analogue Scale for Utility Measurement in End-Stage Liver Disease Pre and Post Transplantation

    Dec 1, 2024, 00:00

  • EE573 Cost-Effectiveness of Older Adult COVID-19 mRNA-1273 and BNT162B2 Vaccination in Italy

    Dec 1, 2024, 00:00

  • EPH82 Characterising Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis Patients in Secondary Care in England

    Dec 1, 2024, 00:00

  • EPH18 Assessment of Cardiovascular Events in Patients With Severe COPD Exacerbations

    Dec 1, 2024, 00:00

  • P49 Cost-Effectiveness (CE) of a Multi-Cancer Early Detection (MCED) Test Varies With Population Cancer Risk

    Dec 1, 2024, 00:00

  • HTA145 Qualitative and Quantitative Evidence Synthesis Strategies to Support JCA and IRA Submissions

    Dec 1, 2024, 00:00

  • HPR100 The Impact of Price Negotiation on the Pricing of Innovative Drugs in China

    Dec 1, 2024, 00:00

  • P41 The Influence of Recall and Timing of Assessment on the Estimation of the QALY When Health Fluctuates Recurrently

    Dec 1, 2024, 00:00

  • HPR8 The Payment for Performance Environment for Drugs and Medical Devices in Romania

    Dec 1, 2024, 00:00

  • HTA20 National Perspectives on the European Joint Clinical Assessment: Insights From HTA Stakeholders in Four Countries

    Dec 1, 2024, 00:00

  • HPR244 Innovative Reimbursement Agreements Addressing the Challenges of Advanced Therapy Medicinal Products: Systematic Review for the Five Major European Healthcare Systems (EU5)

    Dec 1, 2024, 00:00

  • EPH224 Trends in Epidemiology and Mortality of Patients With Coronary Heart Disease in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • HSD25 Requirements to Ensure Patient Safety Through Paxlovid® Prescribing Supports in the Primary Care Setting in Ireland

    Dec 1, 2024, 00:00

  • EE751 Direct Costs of RSV Cases (2022-2023 and 2023-2024 Seasons) in Hospitalized Patients and Out-Patients (Aged ≥60 Years) Prospectively Identified in Valladolid, Spain

    Dec 1, 2024, 00:00

  • CO8 A Retrospective Analysis of the Impact of Approved Anti-Obesity Medications on Cardiovascular Disease Risk Among Patients With Obesity

    Dec 1, 2024, 00:00

  • EE659 Is Universal Genetic Testing Cost-Effective to Detect and Manage Lynch Syndrome in Singapore?

    Dec 1, 2024, 00:00

  • EE798 Evaluating the Potential Health and Economic Impact of V116, an Adult Specific 21-Valent Pneumococcal Conjugate Vaccine, on Invasive Pneumococcal Disease in Germany

    Dec 1, 2024, 00:00

  • CO31 Clinical Benefits of CDK 4/6 Inhibitors in HR+ HER2- Metastatic Breast Cancer: A Systematic Review

    Dec 1, 2024, 00:00

  • HSD43 Pain and Lesion Count in the Clinical Management of Actinic Keratosis in the Real-World Setting

    Dec 1, 2024, 00:00

  • EE754 Challenges in Identifying Information to Build Economic Evaluations in Hereditary Angioedema

    Dec 1, 2024, 00:00

  • EE493 Cost-Utility Analysis of Trastuzumab Deruxtecan Versus Treatment of Physician’s Choice in HER2-Positive Metastatic Breast Cancer in Chinese Setting

    Dec 1, 2024, 00:00

  • A Systematic Literature Review and Meta-Analysis of Primary Evidence Reporting Health-State Preference Values in Chronic Hepatitis B, C, and D

    Dec 1, 2024, 00:00

  • EE670 Impact of Different Mapping Algorithms From Disease-Specific Measures to EQ-5D on Cost-Effectiveness Analysis in Atopic Dermatitis

    Dec 1, 2024, 00:00

  • EE553 Model-Projected Clinical Outcomes of Exagamglogene Autotemcel (exa-cel) in Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises in Canada

    Dec 1, 2024, 00:00

  • EPH42 The Healthcare Resource Use Impact in Adults With Type 1 Diabetes Who Switched From a First to Another First or Next-Generation Basal Insulin Analogue: A Retrospective Linked Primary and Secondary Care Database Study in England

    Dec 1, 2024, 00:00

  • HTA78 Health Technology Assessment (HTA) Key Drivers for Oral Oncology Products: Comparison Between Brazil and European Countries

    Dec 1, 2024, 00:00

  • EE694 A Cost-Effectiveness Analysis of Radiofrequency Renal Denervation for Uncontrolled Hypertension Based on the SPYRAL HTN-ON Med Trial in the Netherlands

    Dec 1, 2024, 00:00

  • Cover

    Dec 1, 2024, 00:00

  • HPR210 Will We Have Access to Healthcare? Escalating Burden of Chronic Disease Hospitalizations: Evidence From Routine Hospital Data

    Dec 1, 2024, 00:00

  • CO69 Indirect Treatment Comparison of Iptacopan Versus Eculizumab and Ravulizumab for Patients With Paroxysmal Nocturnal Hemoglobinuria Naive to C5 Inhibitors

    Dec 1, 2024, 00:00

  • HTA18 First to Launch, First to Falter? An Investigation Into the Clinical Benefits and HTA Outcomes for First-in-Class Drugs

    Dec 1, 2024, 00:00

  • EE624 Budget Impact of Intravenous Eptinezumab in the Prevention of Chronic Migraine Patients in United Arab Emirates

    Dec 1, 2024, 00:00

  • EE726 Budget Impact Analysis of Midline, Short Peripheral and, PICC Catheters for Peripheral Intravenous Infusions

    Dec 1, 2024, 00:00

  • EE829 Quantifying Disease-Specific Indirect Economic Burden Using Survey Research Methods as a Component of Estimating the Total Economic Burden of a Disease

    Dec 1, 2024, 00:00

  • EE700 The Budget Impact of Venetoclax Plus Obinutuzumab for First-Line Chronic Lymphocytic Leukemia in Saudi Arabia

    Dec 1, 2024, 00:00

  • CO105 Impact of Glucagon-like Peptide 1 Receptor Agonist (GLP-1 RA) Non-Persistence on Body Mass Index, HBA1C, and Lipids: Analysis of Over 190,000 Adults Treated With Semaglutide, Liraglutide, and Tirzepatide in US Real-World Data

    Dec 1, 2024, 00:00

  • EPH189 Navigating Methodological Challenges and Informed Consent in Pediatric Research: A Scoping Literature Review

    Dec 1, 2024, 00:00

  • HPR178 Quantifying Health Inequity: An Umbrella Review of Systematic Literature Reviews on Sex-Based Differences in Health Outcomes

    Dec 1, 2024, 00:00

  • HTA49 Analysis of Funding Conditions for Orphan Medicines in Spain: Trends in Pricing Reimbursement

    Dec 1, 2024, 00:00

  • HTA198 Precedents for Reimbursed Highly Specialised Technologies Appraised By the National Institute for Health and Care Excellen Key Takeaways and Recommendations

    Dec 1, 2024, 00:00

  • EE562 Public Health Impact and Cost-Effectiveness of Replacing PCV13 With PCV15 in the National Immunization Program in Saudi Arabia

    Dec 1, 2024, 00:00

  • EE572 Pharmaco-Economic Evaluation of Therapeutic Drug Monitoring of 5-Fluorouracil in the Treatment of Colorectal Cancer

    Dec 1, 2024, 00:00

  • EPH25 US Benchmark Data on Healthcare System Encounter-Related Time Toxicity: Top Conditions at the Population Level

    Dec 1, 2024, 00:00

  • EE286 Cost-Effectiveness of Nirmatrelvir/Ritonavir in Swedish Adults, Stratified by Age, Comorbidity and Vaccination Status, Compared to No Anti-Viral Treatment

    Dec 1, 2024, 00:00

  • HPR165 Pharmacoeconomic Evaluation Exemption and Deferral in Korea – Impact on Patient Access?

    Dec 1, 2024, 00:00

  • HPR72 Coverage Evolution of Anti-Hemophilic Medicines Into the Public Health System of a Middle-Income Country

    Dec 1, 2024, 00:00

  • EE236 Budget Impact Analysis of Biologic Drugs According to Persistance in the Treatment of Psoriasis and Psoriatic Arthritis in the Balearic Islands

    Dec 1, 2024, 00:00

  • HTA206 For Orphan Drugs Technology Assessments, One Size May Not Fit All: Will the Implementation of JCA Lead to Increased Access or Will It Just Lead to a Duplication of Work?

    Dec 1, 2024, 00:00

  • EPH232 Unveiling the Hidden Burden: Respiratory Syncytial Virus in Dutch Older Adults and the Imperative Need for Vaccination

    Dec 1, 2024, 00:00

  • EE391 Psychometric Performance of EQ-5D-5L and VILL-UI, a New Condition-Specific Preference-Weighted Measure, in Patients With Age-Related Macular Degeneration: A Macustar Study Report

    Dec 1, 2024, 00:00

  • HPR36 Balancing Trade-Offs With Simulation-Guided Negotiation: A Probabilistic Tipping Point Analysis for Comparison of Value-Based Contracts and Flat Discount Reimbursement Models for Cell and Gene Therapies

    Dec 1, 2024, 00:00

  • EPH156 Estimated Public Health Impact of Italian Smokers Switching to Smoke-Free Products: A Population Health Impact Modeling Study

    Dec 1, 2024, 00:00

  • P12 How Does Unpaid Caregiving Affect EQ-5D? Does the Average Treatment Effect Differ for 3L and 5L?

    Dec 1, 2024, 00:00

  • HTA104 Equity Is Not Equal: A Comparative Study of How Equity Is Considered by NICE, ICER, CDA-AMC, and PBAC

    Dec 1, 2024, 00:00

  • HPR48 Relationship Between Genetic Heterogeneity and Acquired Resistance to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Targeted Literature Review

    Dec 1, 2024, 00:00

  • PT32 Economic Evaluation of Abdominal Aortic Aneurysm Screening in the Czech Republic

    Dec 1, 2024, 00:00

  • EE690 The Impact of Caring for an Infant With Respiratory Syncytial Virus on Work-Related Outcomes: Insights From Caregivers Recruited From Canada, Germany, Italy, and Netherlands

    Dec 1, 2024, 00:00

  • HTA11 Early Access Programs (EAPs) in Fran Reasons for Refusal

    Dec 1, 2024, 00:00

  • HPR39 Determinants of Prices of Oncological Drugs in France

    Dec 1, 2024, 00:00

  • HPR35 Influence of Pharmaceutical Competition on Compensable Price Differential (EMI): A Dynamic in Favor of Freely Negotiated Hospital Price?

    Dec 1, 2024, 00:00

  • EE765 The Economic Burden of Mild Cognitive Impairment and Dementia Due to Alzheimer’s Disease in South Korea and Taiwan

    Dec 1, 2024, 00:00

  • EPH128 COVID-19 Is Here to Stay: Seasonal Endemic SARS-CoV-2 Infection Patterns Indicate Recurring Waves Adding to Respiratory and Cardiovascular Disease Burden in Germany

    Dec 1, 2024, 00:00

  • HTA149 From Pilot to Practi Insights From the NICE Early Value Assessment for Digital Health Technologies

    Dec 1, 2024, 00:00

  • EE294 Evaluating the Economic Burden of Therapeutic Inertia in People With Type 2 Diabetes in Saudi Arabia

    Dec 1, 2024, 00:00

  • EE547 Budget Impact Analysis of Epcoritamab for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy in Greece

    Dec 1, 2024, 00:00

  • Methods for Measuring and Valuing Informal Care: A Systematic Review and Meta-Analysis in Stroke [Editor's Choice]

    Dec 1, 2024, 00:00

  • HSD111 Cost-Outcome Descriptive Analysis of an Internet Based Treatment for Depression, Social Anxiety, and Panic Disorder: A Post-Implementation Open Naturalistic Design Study

    Dec 1, 2024, 00:00

  • HTA19 Predicting Acceptability of Quantitative Evidence Synthesis for Joint Clinical Assessment Submissions: A Rating Scale

    Dec 1, 2024, 00:00

  • EE814 Potential Return on Subscription to a Smartphone Based Biometric Health Risk Assessment Tool

    Dec 1, 2024, 00:00

  • EE411 Budget Impact Analysis of Subcutaneous Infliximab (CT-P13 SC) for Treating Inflammatory Bowel Disease in Saudi Arabia: Analysis from Payer Perspective

    Dec 1, 2024, 00:00

  • HTA17 NICE Early Value Assessment: A New Avenue for Evidence Generation and Early Market Access in the Digital Therapeutics Space in the United Kingdom

    Dec 1, 2024, 00:00

  • EE697 Cost-Effectiveness of Blood-Based Non-Invasive Testing Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Veteran Population

    Dec 1, 2024, 00:00

  • HPR96 Price Monitoring of Anticancer Drugs Under Price Controlled Category in India

    Dec 1, 2024, 00:00

  • HTA214 Trends Underlying Positive and Negative Decision-Making for New Treatments Targeting Rare Diseases (RD) Appraised by the National Institute for Health and Care Excellence (NICE) in 2023

    Dec 1, 2024, 00:00

  • EE265 Cost-Effectiveness of Brexucabtagene Autoleucel for the Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 26 Years or Older in Greece

    Dec 1, 2024, 00:00

  • HTA147 The Butterfly Effect: Impact of EU HTA on Price Evolution Via International Reference Pricing

    Dec 1, 2024, 00:00

  • EE475 Cost-Benefit Analysis of Difficult Airway Management Techniques in Ukraine

    Dec 1, 2024, 00:00

  • HPR173 Literature Analysis of Artificial Intelligence Applications in Clinical Trial Design for Enhanced Efficiency and Patient Outcomes

    Dec 1, 2024, 00:00

  • HTA70 Insights into NICE's Approach to Uncertainties in Health Technology Appraisals

    Dec 1, 2024, 00:00

  • EE712 Economic and Clinical Impact of Immunization With Nirsevimab Among All Infants in Their First RSV Season Against Standard of Care in Japan

    Dec 1, 2024, 00:00

  • HPR82 Feasibility Study on the Possibilities for Implementation of National Screen Program for Lung Cancer in CEE Countries With Focus on the Balkan Region

    Dec 1, 2024, 00:00

  • EPH112 Prevalence and Costs of Potentially Inappropriate Medications for Elderly People Using Automated Multidose Dispensing Servi A Nationwide Register-Based Study

    Dec 1, 2024, 00:00

  • EE246 A Budget Impact Model Assessing Continuous Blood Glucose Monitoring Devices in Type 2 Diabetes Mellitus in Sweden

    Dec 1, 2024, 00:00

  • HTA127 The Innovative Medicines Fund or the In Need of Medicines Fund: Analysis of NICE Technology Appraisals to Explore Barriers to Managed Access Agreements

    Dec 1, 2024, 00:00

  • HSD113 Pilot Project for Implementing Value-Based Healthcare in Rheumatology for Inflammatory Arthritis Patients

    Dec 1, 2024, 00:00

  • HPR156 Understanding the Key Drivers, Barriers, and the Role of Different Socio-Economic Conditions When Vaccinating Against Invasive Meningococcal Serogroup B Disease in Europe: A Multi-Country Cross-Sectional Physician Survey

    Dec 1, 2024, 00:00

  • Editorial Board

    Nov 5, 2024, 08:49

  • Linking Reimbursement to Patient Benefits for Advanced Therapy Medicinal Products and Other High-Cost Innovations: Policy Recommendations for Outcomes-Based Agreements in Europe

    Nov 1, 2024, 00:00

  • Valuation of Multidimensional Health States With a Bolt-On: Is There a Shortcut? [Editor's Choice]

    Nov 1, 2024, 00:00

  • An Exploratory Study of Alternative Time Frames and Descriptors for EQ-5D-5L in Obstructive Airway Diseases Using Mixed Methods

    Nov 1, 2024, 00:00

  • Table of Contents

    Nov 1, 2024, 00:00

  • When Are You Recovered? Defining Cutoff Points Using the Acute Respiratory Tract Infection Questionnaire

    Nov 1, 2024, 00:00

  • How Many Monte Carlo Samples Are Needed for Probabilistic Cost-Effectiveness Analyses?

    Nov 1, 2024, 00:00

  • Choice Consistency in Discrete Choice Experiments: Does Numeracy Skill Matter?

    Nov 1, 2024, 00:00

  • Development of a Prioritization Framework to Aid Healthcare Funding Decision Making in Health Technology Assessment in Australia: Application of Multicriteria Decision Analysis

    Nov 1, 2024, 00:00

  • EQ-5D-5L Population Scores in Mainland China: Results From a Nationally Representative Survey 2021

    Nov 1, 2024, 00:00

  • Attribute Development in Health-Related Discrete Choice Experiments: A Systematic Review of Qualitative Methods and Techniques to Inform Quantitative Instruments [Editor's Choice]

    Nov 1, 2024, 00:00

  • Recommendations on the Use of Structured Expert Elicitation Protocols for Healthcare Decision Making: A Good Practices Report of an ISPOR Task Force [Editor's Choice]

    Nov 1, 2024, 00:00

  • Informing the United States Medicare Drug Price Negotiation for Apixaban and Rivaroxaban: Methodological Considerations for Value Assessments Many Years After Launch

    Nov 1, 2024, 00:00

  • Clinical Outcome Assessments Are Never “Validated” [Editor's Choice]

    Nov 1, 2024, 00:00

  • Measuring Healthcare Experiences Among People With Intellectual Disability: A Rapid Evidence Synthesis of Tools and Methods

    Nov 1, 2024, 00:00

  • Assessing the Health and Welfare Benefits of Interventions Using the Wider Societal Impacts Framework [Editor's Choice]

    Nov 1, 2024, 00:00

  • Key Issues of Economic Evaluations for Health Technology Assessment in China: A Nationwide Expert Survey

    Nov 1, 2024, 00:00

  • First-Line Treatment With Atezolizumab Plus Bevacizumab and Chemotherapy for US Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: A Cost-Effectiveness Analysis

    Nov 1, 2024, 00:00

  • The Cost-Effectiveness of Germline BReast CAncer Gene Testing in Metastatic Prostate Cancer Followed by Cascade Testing of First-Degree Relatives of Mutation Carriers

    Nov 1, 2024, 00:00
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8 (current)
  • 9
  • 10
  • »